Related Experiment Video
Updated: Jun 25, 2026
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
Published on: September 16, 2019
Current constructs and targets in clinical development for antibody-based cancer therapy
1Innere Klinik II, Department of Oncology, Klinikum Brandenburg an der Havel, Hochstrasse 29, Brandenburg, Germany. deckert@klinikum-brandenburg.de
Current Drug Targets
|February 10, 2009
Summary
Monoclonal antibodies are advancing cancer therapy through novel recombinant constructs and diverse mechanisms beyond immune activation. These antibody therapeutics show promise for targeted cancer treatment, with many in clinical development.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Monoclonal antibodies (mAbs) offer targeted cancer therapy, evolving from early concepts to approved clinical applications.
- Diverse mAb constructs (murine, humanized, fully human, fusion) and mechanisms (cytotoxicity, anti-angiogenesis, growth factor inhibition) are utilized.
- Antibodies increasingly compete with small-molecule drugs in targeting pathways like angiogenesis and growth factors.
Purpose of the Study:
- To review current trends in antibody-based cancer therapeutics in clinical development.
- To identify key directions in the evolution of antibody design and function for cancer therapy.
Main Methods:
- Review of clinical trial data for over 400 antibody-based therapeutics.
- Analysis of trends in antibody construct design and mechanisms of action.
- Selection of specific antibodies for detailed examination of developmental trajectories.
Main Results:
- Two major trends observed: increasing use of molecularly defined recombinant constructs and a shift from classical immune activation towards direct target modulation (inhibition or stimulation).
- Antibodies are being engineered with additional functional moieties attached to the antibody scaffold.
- Despite new trends, conventional Fc receptor-activating antibodies continue to progress through clinical trials with notable success.
Conclusions:
- The future of antibody development for cancer therapy involves highly defined recombinant constructs and novel mechanisms of action.
- Engineered antibodies with enhanced functionalities represent a significant advancement in targeted cancer treatment.
- Conventional antibody designs remain relevant and continue to demonstrate efficacy in clinical settings.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...